Intraocular pressure-lowering effects and safety of brimonidine/brinzolamide fixed combination after switching from other medications

[1] Djafari F(2009)Determinants of adherence to glaucoma medical therapy in a long-term patient population J Glaucoma 18 238-243

[2] Lesk MR(2020)Phase III study to evaluate the efficacy and safety of novel brimonidine/brinzolamide ophthalmic suspension compared with brinzolamide ophthalmic suspension in patients with primary open-angle glaucoma (broad-definition) or ocular hypertension Atarashii Ganka. 37 1299-1308

[3] Harasymowycz PJ(2020)Phase III study to evaluate the efficacy and safety of novel brimonidine/brinzolamide ophthalmic suspension compared with brimonidine ophthalmic solution in patients with primary open-angle glaucoma (broad-definition) or ocular hypertension Atarashii Ganka. 37 1289-1298

[4] Desjardins D(2022)Prescriptions and short-term efficacy of brimonidine/brinzolamide fixed combination eye drops Atarashii Ganka. 39 226-229

[5] Lachaine J(2014)Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension Adv Ther 31 1213-1227

[6] Aihara M(2020)Comparison of the intraocular pressure-lowering efficacy and safety of the brinzolamide/brimonidine fixed-dose combination versus concomitant use of brinzolamide and brimonidine for management of open-angle glaucoma or ocular hypertension Clin Ophthalmol 14 221-230

[7] Sekiya T(2014)Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension Ophthalmology 121 2348-2355

[8] Aihara M(undefined)undefined undefined undefined undefined-undefined

[9] Sekiya T(undefined)undefined undefined undefined undefined-undefined

[10] Inoue K(undefined)undefined undefined undefined undefined-undefined

[1] Djafari F(2009)Determinants of adherence to glaucoma medical therapy in a long-term patient population J Glaucoma 18 238-243

[2] Lesk MR(2020)Phase III study to evaluate the efficacy and safety of novel brimonidine/brinzolamide ophthalmic suspension compared with brinzolamide ophthalmic suspension in patients with primary open-angle glaucoma (broad-definition) or ocular hypertension Atarashii Ganka. 37 1299-1308

[3] Harasymowycz PJ(2020)Phase III study to evaluate the efficacy and safety of novel brimonidine/brinzolamide ophthalmic suspension compared with brimonidine ophthalmic solution in patients with primary open-angle glaucoma (broad-definition) or ocular hypertension Atarashii Ganka. 37 1289-1298

[4] Desjardins D(2022)Prescriptions and short-term efficacy of brimonidine/brinzolamide fixed combination eye drops Atarashii Ganka. 39 226-229

[5] Lachaine J(2014)Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension Adv Ther 31 1213-1227

[6] Aihara M(2020)Comparison of the intraocular pressure-lowering efficacy and safety of the brinzolamide/brimonidine fixed-dose combination versus concomitant use of brinzolamide and brimonidine for management of open-angle glaucoma or ocular hypertension Clin Ophthalmol 14 221-230

[7] Sekiya T(2014)Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension Ophthalmology 121 2348-2355

[8] Aihara M(undefined)undefined undefined undefined undefined-undefined

[9] Sekiya T(undefined)undefined undefined undefined undefined-undefined

[10] Inoue K(undefined)undefined undefined undefined undefined-undefined